2024-02-29 2025-02-28 false Capium Accounts Production 1.1 14657510 2024-02-29 2025-02-28 14657510 bus:AbridgedAccounts 2024-02-29 2025-02-28 14657510 bus:FRS102 2024-02-29 2025-02-28 14657510 bus:AuditExemptWithAccountantsReport 2024-02-29 2025-02-28 14657510 bus:SmallCompaniesRegimeForAccounts 2024-02-29 2025-02-28 14657510 bus:PrivateLimitedCompanyLtd 2024-02-29 2025-02-28 14657510 2024-02-29 2025-02-28 14657510 2025-02-28 14657510 bus:RegisteredOffice 2024-02-29 2025-02-28 14657510 core:WithinOneYear 2025-02-28 14657510 core:AfterOneYear 2025-02-28 14657510 1 2024-02-29 2025-02-28 14657510 bus:Director1 2024-02-29 2025-02-28 14657510 bus:Director1 2025-02-28 14657510 bus:Director1 2023-02-13 2024-02-28 14657510 2023-02-13 14657510 bus:LeadAgentIfApplicable 2024-02-29 2025-02-28 14657510 2023-02-13 2024-02-28 14657510 2024-02-28 14657510 core:WithinOneYear 2024-02-28 14657510 core:AfterOneYear 2024-02-28 14657510 bus:EntityAccountantsOrAuditors 2023-02-13 2024-02-28 14657510 core:CostValuation core:Non-currentFinancialInstruments 2025-02-28 14657510 core:CostValuation core:Non-currentFinancialInstruments 2024-02-28 14657510 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-02-28 14657510 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-02-28 14657510 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-02-28 14657510 core:Non-currentFinancialInstruments 2025-02-28 14657510 core:Non-currentFinancialInstruments 2024-02-28 14657510 core:ShareCapital 2025-02-28 14657510 core:ShareCapital 2024-02-28 14657510 core:RetainedEarningsAccumulatedLosses 2025-02-28 14657510 core:RetainedEarningsAccumulatedLosses 2024-02-28 14657510 dpl:Item1 2024-02-29 14657510 dpl:Item1 2025-02-28 14657510 dpl:Item1 2023-02-13 14657510 dpl:Item1 2024-02-28 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 14657510
H.S PHARMACEUTICALS LTD
Abridged Accounts
Period of accounts Start date: 29 February 2024 End date: 28 February 2025

H.S Pharmaceuticals LTD Contents Page For the year ended 28 February 2025
Accountants' report | 1
Statement of financial position | 2
Notes to the financial statements | 3

H.S Pharmaceuticals LTD Accountants' Report For the year ended 28 February 2025
Accountant’s report You consider that the company is exempt from an audit for the year ended 28 February 2025 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year. In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us. We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts. Sovereign Accountants 28 February 2025 .................................................... Sovereign Accountants 6 Blenheim Court Peppercorn Close Peterborough PE1 2DU 08 October 2025 1

H.S Pharmaceuticals LTD Statement of Financial Position As at 28 February 2025
| Notes | 2025 £ |  | 2024 £
--- | --- | --- | --- | ---
Current assets |  |  |
Debtors |  | 10,850 |  | 4,543
Cash at bank and in hand |  | 4 |  | 504
|  | 10,854 |  | 5,047
Creditors: amount falling due within one year |  | (5,998) |  | (5,709)
Net current assets |  | 4,856 |  | (662)
Total assets less current liabilities |  | 4,856 |  | (662)
Net assets |  | 4,856 |  | (662)
Capital and reserves |  |  |
Called up share capital |  | 1 |  | 1
Profit and loss account |  | 4,855 |  | (663)
Shareholders' funds |  | 4,856 |  | (662)
For the year ended 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A). The financial statements were approved by the director on 08 October 2025 and were signed by:
------------------------------- Haider Shamim Director
2

H.S Pharmaceuticals LTD Notes to the Abridged Financial Statements For the year ended 28 February 2025
General Information H.S Pharmaceuticals LTD is a private company, limited by shares, registered in , registration number 14657510, registration address 495 Gladstone Street, PE1 2DQ. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies. The financial statements are prepared in sterling which is the functional currency of the company.
2. | Average number of employees Average number of employees during the year was 1 (2024 : 0).
3